Table 3.
Subgroup | Median nerve MCV | Median nerve SCV | ||||
Studies | Patient | MD (95% CI) | Studies | Patient | MD (95CI) | |
Dose | ||||||
Intravenous infusion 20 ml | 2[23,27] | 146 | 3.11 (1.97–4.25) | 2[23,27] | 146 | 4.73 (2.33–7.14) |
Intravenous infusion 15ml | 2[25,32] | 160 | 9.00 (7.28–10.72) | 2[25,32] | 160 | 7.21 (5.89–8.54) |
Intravenous infusion 10ml | 6[24,29–31,35–36] | 597 | 4.86 (3.77–5.96) | 6[24,29–31,35–36] | 597 | 4.49 (2.97–6.01) |
Acupoint injection 1ml | 2[28,37] | 160 | 4.80 (3.05–6.54) | 2[28,37] | 160 | 3.95 (2.38 –5.53) |
Test for subgroup differences: p < 0.001, I2 = 90.4% | Test for subgroup differences: P = 0.007, I2 = 75.2% | |||||
Treatment duration | ||||||
2 weeks | 6[23–25,29,32,34,35] | 519 | 6.61 (4.52–8.70) | 6[23–25,29,32,34,35] | 519 | 6.23 (5.27–7.18) |
3 weeks | 3[27,31,36] | 284 | 3.88 (2.56–5.21) | 3[27,31,36] | 284 | 4.46 (3.16–5.76) |
4 weeks | 1[30] | 100 | 3.70 (1.90–5.50) | 1[30] | 100 | 1.90 (0.29–3.51) |
8 weeks | 2[28,37] | 160 | 4.80 (3.05–6.54) | 2[28,37] | 160 | 3.95 (2.38–5.53) |
Test for subgroup differences: p = 0.13, I2 = 46.6% | Test for subgroup differences: P < 0.001, I2 = 86.6% | |||||
Manufactor | ||||||
Guizhou Baite | 6[23,25,30–32,35] | 603 | 5.95 (3.88–8.03) | 6[23,25,30–32,35] | 603 | 4.97 (3.14–6.80) |
Jilin Sichang | 2[28,36] | 190 | 4.95 (3.40–6.50) | 2[28,36] | 190 | 3.77 (2.43–5.11) |
Other | 4[24,27,29,37] | 270 | 4.70 (2.38–7.02) | 4[24,27,29,37] | 270 | 5.36 (4.42–6.31) |
Test for subgroup differences: p = 0.68, I2 = 0% | Test for subgroup differences: P = 0.16, I2 = 45.3% |